Bilgehan Yüzbaşıoğlu
Bilgehan Yüzbaşıoğlu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Nurhan Demir
Istanbul Haseki Training and Research Hospital, 34096 Fatih, Türkiye
3 shared publications - Emine Kanatsız
Department of Gastroenterology, Umraniye Training and Research Hospital, Istanbul, Turkey
1 shared publication - Kamil Özdil
Department of Gastroenterology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkiye
1 shared publication - Müge Ustaoğlu
Department of Gastroenterology, Faculty of Medicine, Ondokuz Mayıs University, Samsun 55270, Turkey
1 shared publication - Saime Gül Barut
Istanbul Haseki Eğitim ve Araştırma Hastanesi
1 shared publication - Savas Ozturk
Division of Nephrology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
1 shared publication
Latest Publications
- 27 September 2023
- Published by Galenos Yayinevi in Medical Bulletin of Haseki
- Vol. 61 (4) , 303-307
Factors Affecting Recurrent Choledocholithiasis After Endoscopic Biliary Sphincterotomy: A Cross-Sectional Study
- 27 September 2023
- Published by Galenos Yayinevi in Medical Bulletin of Haseki
- Vol. 61 (4) , 303-307
Factors Affecting Recurrent Choledocholithiasis After Endoscopic Biliary Sphincterotomy: A Cross-Sectional Study
- 19 September 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (3) , 265-269
Diagnostic Prevalence of Celiac Disease by Routine Duodenum Biopsy in Adult Patients with Iron Deficiency
- 19 September 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (3) , 265-269
Diagnostic Prevalence of Celiac Disease by Routine Duodenum Biopsy in Adult Patients with Iron Deficiency
- Open Access
- 1 January 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 1734896
Prevalence and Prognostic Importance of High Fibrosis‐4 Index in COVID‐19 Patients
Introduction. The fibrosis 4 (FIB‐4) index was developed to predict advanced fibrosis in patients with liver disease. We aimed to evaluate the association of FIB‐4 with risk factors for progression to critical illness in middle‐aged patients hospitalized for coronavirus disease 2019 (COVID‐19). Method. We included patients aged 35–65 years who were hospitalized following a positive RT‐PCR SARS‐Cov‐2 test in a tertiary hospital. All data were obtained from the medical records of the patients during the first admission to the hospital. The FIB‐4 index was calculated according to the equation (age (years) x AST (IU/L)/platelet count (109/L)/√ALT (IU/L)). The FIB‐4 index was divided into three categories according to the score categorisation: 2.67 = high risk. Results. A total of 619 confirmed COVID‐19 patients (mean age = 52 yrs.) were included in this study; 37 (6.0%) were admitted to the intensive care unit (ICU), of which 44% were intubated and eight (1.3%) patients died during follow‐up. The results of patients with high FIB‐4 scores were compared with those with low FIB‐4 scores. In patients with high FIB‐4 scores, male gender, and advanced age, decreased neutrophil, lymphocyte, thrombocyte, and albumin counts, elevated AST, LDH, CK, ferritin, CRP, and D‐dimer, and low GFR were the high‐risk factors for critical illness. Additionally, the number of patients referred to ICU with high FIB‐4 who died had higher scores than from those with low scores. Conclusion. The FIB‐4 index derived from baseline data obtained during hospitalisation can be used as a simple, inexpensive, and straightforward indicator to predict ICU requirement and/or death in middle‐aged hospitalized COVID‐19 patients.
- 1 January 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 1734896
Open AccessPrevalence and Prognostic Importance of High Fibrosis‐4 Index in COVID‐19 Patients
Introduction. The fibrosis 4 (FIB‐4) index was developed to predict advanced fibrosis in patients with liver disease. We aimed to evaluate the association of FIB‐4 with risk factors for progression to critical illness in middle‐aged patients hospitalized for coronavirus disease 2019 (COVID‐19). Method. We included patients aged 35–65 years who were hospitalized following a positive RT‐PCR SARS‐Cov‐2 test in a tertiary hospital. All data were obtained from the medical records of the patients during the first admission to the hospital. The FIB‐4 index was calculated according to the equation (age (years) x AST (IU/L)/platelet count (109/L)/√ALT (IU/L)). The FIB‐4 index was divided into three categories according to the score categorisation: 2.67 = high risk. Results. A total of 619 confirmed COVID‐19 patients (mean age = 52 yrs.) were included in this study; 37 (6.0%) were admitted to the intensive care unit (ICU), of which 44% were intubated and eight (1.3%) patients died during follow‐up. The results of patients with high FIB‐4 scores were compared with those with low FIB‐4 scores. In patients with high FIB‐4 scores, male gender, and advanced age, decreased neutrophil, lymphocyte, thrombocyte, and albumin counts, elevated AST, LDH, CK, ferritin, CRP, and D‐dimer, and low GFR were the high‐risk factors for critical illness. Additionally, the number of patients referred to ICU with high FIB‐4 who died had higher scores than from those with low scores. Conclusion. The FIB‐4 index derived from baseline data obtained during hospitalisation can be used as a simple, inexpensive, and straightforward indicator to predict ICU requirement and/or death in middle‐aged hospitalized COVID‐19 patients.
- Open Access
- 15 December 2019
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 30 (12) , 1025-1029
Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease
Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13) in patients with IBD and to assess their possible role in the etiopathogenesis of the disease. Materials and Methods: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn’s disease) and 20 healthy controls were included in the present study. TAFI, TFPI, and ADAMTS-13 concentrations were determined by enzyme-linked immunosorbent assay. Results: Mean TAFI, TFPI, and ADAMTS-13 concentrations in the patient group were 17.75 ng/ml, 72.10 ng/ml, and 14.90 U/l, respectively. In the control group, these values were 117.10 ng/ml, 300 ng/ml, and 191.55 U/l, respectively. TAFI, TFPI, and ADAMTS-13 values were significantly lower in the patient group than in the control group (all p<0.01). Conclusion: TAFI, TFPI, and ADAMTS-13 levels were significantly lower in the patient group. These findings indicate the presence of a clear, multifactorial imbalance in the coagulation–fibrinolytic system in the patient group. It is also possible that this imbalance in the coagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.
- 15 December 2019
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 30 (12) , 1025-1029
Open AccessLevels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease
Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13) in patients with IBD and to assess their possible role in the etiopathogenesis of the disease. Materials and Methods: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn’s disease) and 20 healthy controls were included in the present study. TAFI, TFPI, and ADAMTS-13 concentrations were determined by enzyme-linked immunosorbent assay. Results: Mean TAFI, TFPI, and ADAMTS-13 concentrations in the patient group were 17.75 ng/ml, 72.10 ng/ml, and 14.90 U/l, respectively. In the control group, these values were 117.10 ng/ml, 300 ng/ml, and 191.55 U/l, respectively. TAFI, TFPI, and ADAMTS-13 values were significantly lower in the patient group than in the control group (all p<0.01). Conclusion: TAFI, TFPI, and ADAMTS-13 levels were significantly lower in the patient group. These findings indicate the presence of a clear, multifactorial imbalance in the coagulation–fibrinolytic system in the patient group. It is also possible that this imbalance in the coagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.